<html>
<head>
<title>
vaccine5.html
</title>
</head>

<body background=assets/vaccine5/novavax1.jpg>

<b>

<font face=calibri body>

<h2>Novavax COVID-19 vaccine</h2>



<p>
<img src=assets/vaccine5/novavax2.jpg align=left height=200 width=350>
<div align=justify>

Novavax COVID-19 vaccine, codenamed NVX-CoV2373, and also called SARS-CoV-2 rS (recombinant spike) protein nanoparticle with Matrix-M1 adjuvant, is a COVID-19 vaccine candidate developed by Novavax and Coalition for Epidemic Preparedness Innovations (CEPI). It requires two doses and is stable at 2 to 8 °C (36 to 46 °F) (refrigerated).

</div>
</p>

<p>
<div align=justify>

Description: NVX-CoV2373 has been described as both a protein subunit vaccine and a virus-like particle vaccine, though the producers call it a "recombinant nanoparticle vaccine".

</div>
</p>

<br>

<p>
<img src=assets/vaccine5/novavax3.jpg align=right height=200 width=350>
<div align=justify>

The vaccine is produced by creating an engineered baculovirus containing a gene for a modified SARS-CoV-2 spike protein. The baculovirus then infects a culture of Sf9 moth cells, which create the spike protein and display it on their cell membranes. The spike proteins are then harvested and assembled onto a synthetic lipid nanoparticle about 50 nanometers across, each displaying up to 14 spike proteins.

</div>
</p>

<br>

<p>
<div align=justify>

The formulation includes a saponin-based adjuvant.

</div>
</p>


<br>
<br>


Source:		<a href=https://en.wikipedia.org/wiki/Novavax_COVID-19_vaccine>		wikipedia.org/wiki/Novavax_COVID-19_vaccine	</a>

<br>
		<a href=vaccine4.html>		<img src=assets/buttons/leftarrow.png align=left height=50 width=50>		</a>
	<div align=center>
		<a href=home.html>		<img src=assets/buttons/homebutton.png align=center height=50 width=100>	</a>
	</div>

</font>
</b>

</body>
</html>